Ligand Pharmaceuticals
LGND
215 hedge funds and large institutions have $2.23B invested in Ligand Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 59 increasing their positions, 89 reducing their positions, and 21 closing their positions.
146% more call options, than puts
Call options by funds: $23.5M | Put options by funds: $9.54M
138% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 21
29% more capital invested
Capital invested by funds: $1.73B → $2.23B (+$496M)
15% more funds holding
Funds holding: 187 → 215 (+28)
34% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 89
40% less funds holding in top 10
Funds holding in top 10: 10 → 6 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$32.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.8M |
| 3 |
Bank of New York Mellon
New York
|
+$19.7M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$18.6M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$24.1M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$20.6M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$18M |
| 4 |
RIM
RS Investment Management
San Francisco,
California
|
-$17.9M |
| 5 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$13.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SGK
226
Steigerwald Gordon & Koch
Leesburg,
Virginia
| – | -$328K | -16,880 | Closed |
|
|
WMSA
227
Weiss Multi-Strategy Advisers
New York
| – | -$771K | -16,030 | Closed |
|
228
Creative Planning
Overland Park,
Kansas
| – | -$699K | -14,523 | Closed |
|
|
GLA
229
Great Lakes Advisors
Chicago,
Illinois
| – | -$691K | -14,358 | Closed |
|
|
TI
230
Trexquant Investment
Stamford,
Connecticut
| – | -$547K | -11,381 | Closed |
|
|
QIM
231
Quantitative Investment Management
Charlottesville,
Virginia
| – | -$462K | -9,618 | Closed |
|
|
LCS
232
Levin Capital Strategies
New York
| – | -$363K | -7,547 | Closed |
|
|
CSS
233
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$363K | -7,539 | Closed |
|
234
SG Americas Securities
New York
| – | -$358K | -7,452 | Closed |
|
235
Nomura Holdings
Tokyo,
Japan
| – | -$326K | -6,874 | Closed |
|
236
Acadian Asset Management
Boston,
Massachusetts
| – | -$99K | -2,058 | Closed |
|
LGND Hedge Fund Activity: Q2 2015 in Review
215 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2015, worth a combined $2.23B — up 29% from $1.73B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new LGND positions and 21 closed out — a net gain of 29 holders — while 59 added to existing stakes and 89 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $32.1M. The largest seller was Goldman Sachs, cutting an estimated $24.1M.
- 215 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2015, up from 187 in Q1 2015.
- Funds reported $2.23B of Ligand Pharmaceuticals stock for Q2 2015, up 29% quarter-over-quarter.
- 50 funds opened new Ligand Pharmaceuticals positions in Q2 2015 and 21 closed out, a net change of +29 holders.
- The largest Ligand Pharmaceuticals buyer in Q2 2015 was T. Rowe Price Associates, an estimated $32.1M added.
- The largest Ligand Pharmaceuticals seller in Q2 2015 was Goldman Sachs, an estimated $24.1M sold.
Based on aggregated 13F filings for Q2 2015.